Epithalon vs Pasireotide
Overview
Epithalon is primarily a sleep & recovery peptide, while Pasireotide is used for hormonal.
This page compares Epithalon and Pasireotide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Epithalon | Pasireotide | |
|---|---|---|
| Category | Sleep & Recovery | Hormonal |
| Regulatory status (US) | Compounding (Rx) — Apr 2026 | FDA approved |
| Typical dosage | 5-10 mg | 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) |
| Frequency | cycle protocol | Twice daily (SC formulation) or every 4 weeks (LAR formulation) |
| Reported benefits | Improved sleep quality, circadian rhythm regulation, anti-aging | Reduction of cortisol hypersecretion in Cushing's disease, normalization of GH and IGF-1 in acromegaly, pituitary tumor volume reduction, improvement of clinical signs of hypercortisolism |
| Reported side effects | Minimal side effects during cycles | Hyperglycemia, new-onset or worsening diabetes mellitus, diarrhea, nausea, cholelithiasis, QT interval prolongation, bradycardia, hepatic enzyme elevation, adrenal insufficiency (hypocortisolism) |
Key differences
Primary use. Epithalon is categorised under Sleep & Recovery, while Pasireotide falls under Hormonal. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Epithalon: not FDA-approved; compounding permitted with a prescription as of April 2026. Pasireotide: FDA-approved.
Dosing. Epithalon is typically dosed at 5-10 mg (cycle protocol). Pasireotide is typically dosed at 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) (Twice daily (SC formulation) or every 4 weeks (LAR formulation)).
Can you stack them?
Some protocols combine peptides, but stacking Epithalon and Pasireotide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Epithalon and Pasireotide?
- Epithalon is primarily a sleep & recovery peptide, while Pasireotide is used for hormonal. Epithalon is not FDA-approved; compounding permitted with a prescription (as of April 2026), whereas Pasireotide is FDA-approved for one or more indications.
- What is Epithalon used for?
- Circadian rhythm regulator.
- What is Pasireotide used for?
- Multi-receptor somatostatin analog (Signifor/Signifor LAR) FDA-approved for Cushing's disease and acromegaly.
- Can you take Epithalon and Pasireotide together?
- Some users combine peptides within a single protocol, but stacking Epithalon and Pasireotide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Epithalon or Pasireotide FDA-approved?
- Epithalon is not FDA-approved; compounding permitted with a prescription (as of April 2026). Pasireotide is FDA-approved for one or more indications.
Read the full articles
- Epithalon — full monograph: mechanism, research, dosing & references
- Pasireotide — full monograph: mechanism, research, dosing & references